Newsroom

LOS ANGELES--(BUSINESS WIRE)--AHCO Investors Have Opportunity to Join AdaptHealth Corp. Fraud Investigation with SBS Law...

LOS ANGELES--(BUSINESS WIRE)--AGCO Investors Have Opportunity to Join AGCO Corporation Fraud Investigation with SBS Law...

LOS ANGELES--(BUSINESS WIRE)--MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law...

LOS ANGELES--(BUSINESS WIRE)--SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law...

WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Energy Vault Holdings, Inc. (NYSE: NRGV) ("Energy Vault"), een wereldwijde marktleider op het gebied van duurzame energie-infrastructuur, heeft vandaag bekendgemaakt dat het een strategische commerciële overeenkomst heeft gesloten. Onder deze overeenkomst gaat Energy Vault batterij-energieopslagsystemen ("BESS"), netvormende stroomomzettingssystemen en AI-infrastructuurbeheersoftware leveren ter ondersteuning van een eerste implementatie van in totaal...

LOS ANGELES--(BUSINESS WIRE)--RESECURITY (USA) is proud to announce our new Partner Membership with the Association of Old Crows (AOC), the premier global organization dedicated to advancing electromagnetic warfare (EW) and spectrum operations. The Association of Old Crows (AOC) is an international professional organization that began in 1964 as a forum for the exchange of technical and operational information. With over 14,000 members internationally, the AOC is dedicated to advancing the art...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating the sale of Forte Biosciences, Inc. (NASDAQ: FBRX) to argenx for $77.00 per share in cash. Halper Sadeh encourages Forte shareholders to click here to learn more about their rights and options or contact Daniel Sadeh or Zachary Halper free of charge at (212) 763-0060 or sadeh@halpersadeh.com or zhalper@halpersadeh.com. The investigation concerns whether Forte and its board of directors violated the federa...

OMAHA, Neb.--(BUSINESS WIRE)--(BRK.A; BRK.B) – Berkshire’s operating results for the second quarter and first six months of 2026 and 2025 are summarized in the following paragraphs. However, we urge investors and reporters to read our 10-Q, which has been posted at www.berkshirehathaway.com. The limited information that follows in this press release is not adequate for making an informed investment judgment. Earnings of Berkshire Hathaway Inc. and its consolidated subsidiaries for the second qu...

維也納--(BUSINESS WIRE)--(美國商業資訊)-- 國際商會(ICC)仲裁庭就AOP Orphan Pharmaceuticals GmbH (“AOP Health”)與PharmaEssentia Corp. (“PharmaEssentia”)之間關於BESREMi® (ropeginterferon alfa-2b)的持續仲裁程序做出一項金額裁定，裁定AOP Health獲得總計約1.12億歐元賠償。該裁定將AOP Health因PharmaEssentia故意違約而提出的損害賠償請求金額確定為約8200萬歐元。同時，仲裁庭還裁定AOP Health獲得約3100萬歐元及利息，做為AOP Health在2019年至2022年期間因PharmaEssentia定價過高而多付之款項的補償。仲裁庭由此確認，PharmaEssentia在上述年份中向AOP Health收取的費用存在高達900%的超額加價。仲裁庭還確認，AOP Health有權將其欠付PharmaEssentia的約1700萬歐元利潤分成款項，與其遠超該金額的AOP Health損害賠償請求進行有效抵銷。...

ウィーン--(BUSINESS WIRE)--（ビジネスワイヤ） -- ICC仲裁裁判所は、PharmaEssentia Corp.との係争中の仲裁手続において下された損害額裁定により、AOP Orphan Pharmaceuticals GmbH（「AOP Health」）に対し、総額約1億1,200万ユーロを裁定しました。ICC仲裁裁判所は、BESREMi®（ロペグインターフェロン アルファ-2b）に関してPharmaEssentia Corp.（以下「PharmaEssentia」）との間で係争中の仲裁手続において下された損害額裁定により、AOP Orphan Pharmaceuticals GmbH（以下「AOP Health」）に対し、総額約1億1,200万ユーロを認めました。同裁定では、PharmaEssentiaによる故意の契約違反に基づくAOP Healthの損害賠償請求額を約8,200万ユーロと認定しています。また、2019年から2022年にかけての過度な価格設定によりAOP HealthがPharmaEssentiaに対して支払った超過支払額の返還として、約3,1...